Lipodystrophy-associated progeroid syndromes

dc.contributor.affiliationUniversidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades Crónicases_ES
dc.contributor.authorAraujo-Vilar, David
dc.contributor.authorFernández-Pombo, Antía
dc.contributor.authorCobelo Gómez, Silvia
dc.contributor.authorCastro, Ana I.
dc.contributor.authorSánchez Iglesias, Sofía
dc.date.accessioned2024-02-05T12:05:39Z
dc.date.available2024-02-05T12:05:39Z
dc.date.issued2022
dc.descriptionThis version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s42000-022-00386-7es_ES
dc.description.abstractWith the exception of HIV-associated lipodystrophy, lipodystrophy syndromes are rare conditions characterized by a lack of adipose tissue, which is not generally recovered. As a consequence, an ectopic deposition of lipids frequently occurs, which usually leads to insulin resistance, atherogenic dyslipidemia, and hepatic steatosis. These disorders include certain accelerated aging syndromes or progeroid syndromes. Even though each of them has unique clinical features, most show common clinical characteristics that affect growth, skin and appendages, adipose tissue, muscle, and bone and, in some of them, life expectancy is reduced. Although the molecular bases of these Mendelian disorders are very diverse and not well known, genomic instability is frequent as a consequence of impairment of nuclear organization, chromatin structure, and DNA repair, as well as epigenetic dysregulation and mitochondrial dysfunction. In this review, the main clinical features of the lipodystrophy-associated progeroid syndromes will be described along with their causes and pathogenic mechanisms, and an attempt will be made to identify which of López-Otín’s hallmarks of aging are present.es_ES
dc.description.peerreviewedSIes_ES
dc.description.sponsorshipThis work was supported by the Instituto de Salud Carlos III and the European Regional Development Fund (ERDF (grant number PI081449), and an intramural grant from the Xunta de Galicia (GPC2014/036, ED341b 2017/19, ED431B 2020/37). A.F.-P. is a Rio Hortega researcher (ISCIII; CM20/00155). S.S.-I. was awarded a Research Fellowship from the Asociación Española de Familiares y Afectados de Lipodistrofias (AELIP).es_ES
dc.identifier.citationAraújo-Vilar, D., Fernández-Pombo, A., Cobelo-Gómez, S. et al. Lipodystrophy-associated progeroid syndromes. Hormones 21, 555–571 (2022).es_ES
dc.identifier.doi10.1007/s42000-022-00386-7
dc.identifier.urihttp://hdl.handle.net/10347/32340
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.rights.accessRightsopen accesses_ES
dc.titleLipodystrophy-associated progeroid syndromeses_ES
dc.typejournal articlees_ES
dc.type.hasVersionAMes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication940b4585-ffa5-4468-9245-f1ea22e28a62
relation.isAuthorOfPublication18abbdb4-47ec-4e3d-9250-d47d15f8c7bd
relation.isAuthorOfPublication.latestForDiscovery940b4585-ffa5-4468-9245-f1ea22e28a62

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022 Araújo-Vilar et al. - Lipodystrophy-associated progeroid syndromes.pdf
Size:
1.17 MB
Format:
Adobe Portable Document Format
Description: